Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with ...
Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.